<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433248</url>
  </required_header>
  <id_info>
    <org_study_id>DC2017RACELINES01</org_study_id>
    <nct_id>NCT03433248</nct_id>
  </id_info>
  <brief_title>Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES</brief_title>
  <acronym>RACELINES</acronym>
  <official_title>RACELINES: Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.H.H. Kramer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study aims to explore the clinical effects and mechanistics of mono- and
      combination therapy with SGLT-2 inhibitor empagliflozin and DPP-4 inhibitor linagliptin on
      renal physiology and biomarkers in metformin-treated T2DM patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sodium-glucose linked transporters (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4)
      inhibitors are relatively novel glucose-lowering drugs for the treatment of T2DM. These
      agents seem to exert pleiotropic actions 'beyond glucose control'. SGLT-2 inhibitors decrease
      proximal sodium reabsorption and decrease glomerular pressure and albuminuria in rodents and
      type 1 diabetes patients. In addition, SGLT-2 inhibitors reduce, blood pressure and body
      weight. In rodents, SGLT-2 inhibitors also improved histopathological abnormalities
      associated with DKD. DPP-4 inhibitors are considered weight neutral, improve lipid profiles
      and slight reductions in blood pressure have been reported. To date, the potential
      renoprotective effects and mechanisms of SGLT-2 inhibitors and combination therapy with
      SGLT-2 inhibitors have not been sufficiently detailed in human type 2 diabetes. The current
      study aims to explore the clinical effects and mechanistics of mono- and combination therapy
      with an SGLT-2 inhibitor and a DPP-4 inhibitor on renal physiology and biomarkers in
      metformin-treated T2DM patients.

      66 patients with type 2 diabetes will undergo a 16-week intervention period with 8-week
      empagliflozin (SGLT-2 inhibitor) monotherapy, followed by 8-week empagliflozin and
      linagliptin (DPP-4 inhibitor) combination therapy or 8-week linagliptin monotherapy, followed
      by 8-week linagliptin and empagliflozin combination therapy or 8-week gliclazide (SU
      derivative), followed by 8-week gliclazide intensification therapy in order to assess changes
      in the outcome parameters.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GFR</measure>
    <time_frame>16 weeks</time_frame>
    <description>Changes from baseline following 16-week treatment on renal hemodynamics in both the fasting and postprandial state, measured as GFR (determined by the inulin-clearance technique)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GFR</measure>
    <time_frame>8 weeks</time_frame>
    <description>Changes from baseline following 8-week treatment on renal hemodynamics in both the fasting and postprandial state, measured as GFR (determined by the inulin-clearance technique)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal tubular function</measure>
    <time_frame>16 weeks</time_frame>
    <description>24-hour urine sodium-, potassium-, chloride-, calcium-, magnesium-, phosphate-, uric acid-, bicarbonate-, ammonium-, urea- and glucose excretion, urine osmolality and urinary pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal tubular function</measure>
    <time_frame>8 weeks</time_frame>
    <description>24-hour urine sodium-, potassium-, chloride-, calcium-, magnesium-, phosphate-, uric acid-, bicarbonate-, ammonium-, urea- and glucose excretion, urine osmolality and urinary pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Damage</measure>
    <time_frame>16 weeks</time_frame>
    <description>24-hour urinary albumin excretion, albumin/creatinine ratio (UCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Damage</measure>
    <time_frame>10 weeks</time_frame>
    <description>24-hour urinary albumin excretion, albumin/creatinine ratio (UCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Damage</measure>
    <time_frame>8 weeks</time_frame>
    <description>24-hour urinary albumin excretion, albumin/creatinine ratio (UCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Damage</measure>
    <time_frame>2 weeks</time_frame>
    <description>24-hour urinary albumin excretion, albumin/creatinine ratio (UCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (Dinamap®)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measured using an automated oscillometric blood pressure device (Dinamap®)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (Dinamap®)</measure>
    <time_frame>10 weeks</time_frame>
    <description>Measured using an automated oscillometric blood pressure device (Dinamap®)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (Dinamap®)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured using an automated oscillometric blood pressure device (Dinamap®)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (Dinamap®)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Measured using an automated oscillometric blood pressure device (Dinamap®)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure (Dinamap®)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measured using an automated oscillometric blood pressure device (Dinamap®)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure (Dinamap®)</measure>
    <time_frame>10 weeks</time_frame>
    <description>Measured using an automated oscillometric blood pressure device (Dinamap®)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure (Dinamap®)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured using an automated oscillometric blood pressure device (Dinamap®)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure (Dinamap®)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Measured using an automated oscillometric blood pressure device (Dinamap®)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body anthropometrics: Body mass index</measure>
    <time_frame>16 weeks</time_frame>
    <description>Body mass index</description>
  </other_outcome>
  <other_outcome>
    <measure>Body anthropometrics: Body mass index</measure>
    <time_frame>8 weeks</time_frame>
    <description>Body mass index</description>
  </other_outcome>
  <other_outcome>
    <measure>Body anthropometrics: Body weight</measure>
    <time_frame>16 weeks</time_frame>
    <description>Body weight</description>
  </other_outcome>
  <other_outcome>
    <measure>Body anthropometrics: Body weight</measure>
    <time_frame>8 weeks</time_frame>
    <description>Body weight</description>
  </other_outcome>
  <other_outcome>
    <measure>Body anthropometrics: Height</measure>
    <time_frame>16 weeks</time_frame>
    <description>Height</description>
  </other_outcome>
  <other_outcome>
    <measure>Body anthropometrics: Height</measure>
    <time_frame>8 weeks</time_frame>
    <description>Height</description>
  </other_outcome>
  <other_outcome>
    <measure>Body anthropometrics: Waist circumference</measure>
    <time_frame>16 weeks</time_frame>
    <description>Waist circumference</description>
  </other_outcome>
  <other_outcome>
    <measure>Body anthropometrics: Waist circumference</measure>
    <time_frame>8 weeks</time_frame>
    <description>Waist circumference</description>
  </other_outcome>
  <other_outcome>
    <measure>Body anthropometrics: Hip circumference</measure>
    <time_frame>16 weeks</time_frame>
    <description>Hip circumference</description>
  </other_outcome>
  <other_outcome>
    <measure>Body anthropometrics: Hip circumference</measure>
    <time_frame>8 weeks</time_frame>
    <description>Hip circumference</description>
  </other_outcome>
  <other_outcome>
    <measure>Body fat content</measure>
    <time_frame>16 weeks</time_frame>
    <description>Body fat content by bioimpedance analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Body fat content</measure>
    <time_frame>8 weeks</time_frame>
    <description>Body fat content by bioimpedance analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure (NexFin®)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure (NexFin®)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart Rate (NexFin®)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart Rate (NexFin®)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke Volume</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke Volume</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac output</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac output</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac index</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac index</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Total systemic vascular resistance</measure>
    <time_frame>16 weeks</time_frame>
    <description>Continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Total systemic vascular resistance</measure>
    <time_frame>8 weeks</time_frame>
    <description>Continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac autonomic nervous system function</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac autonomic nervous system function</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Microvascular function</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Microvascular function</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessed by radial artery applanation tonometry (SphygmoCor®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessed by radial artery applanation tonometry (SphygmoCor®)</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin sensitivity (M-value)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Derived from the glucose infusion rate during the euglycemic clamp (M-value)</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin sensitivity (M-value)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Derived from the glucose infusion rate during the euglycemic clamp (M-value)</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin sensitivity (OGIS)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Meal tolerance test (OGIS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin sensitivity (OGIS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Meal tolerance test (OGIS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin sensitivity (Matsuda index)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Meal tolerance test (Matsuda index)</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin sensitivity (Matsuda index)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Meal tolerance test (Matsuda index)</description>
  </other_outcome>
  <other_outcome>
    <measure>Beta-cell function (insulinogenic index)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Meal tolerance test (insulinogenic index)</description>
  </other_outcome>
  <other_outcome>
    <measure>Beta-cell function (insulinogenic index)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Meal tolerance test (insulinogenic index)</description>
  </other_outcome>
  <other_outcome>
    <measure>Beta-cell function (HOMA-B)</measure>
    <time_frame>16 weeks</time_frame>
    <description>HOMA-B</description>
  </other_outcome>
  <other_outcome>
    <measure>Beta-cell function (HOMA-B)</measure>
    <time_frame>8 weeks</time_frame>
    <description>HOMA-B</description>
  </other_outcome>
  <other_outcome>
    <measure>Beta-cell function (ratio of postprandial glucose and C-peptide)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Meal tolerance test (ratio of postprandial glucose and C-peptide)</description>
  </other_outcome>
  <other_outcome>
    <measure>Beta-cell function (ratio of postprandial glucose and C-peptide)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Meal tolerance test (ratio of postprandial glucose and C-peptide)</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid spectrum</measure>
    <time_frame>16 weeks</time_frame>
    <description>(triglycerides (TG), total-cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C)</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid spectrum</measure>
    <time_frame>8 weeks</time_frame>
    <description>(triglycerides (TG), total-cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C)</description>
  </other_outcome>
  <other_outcome>
    <measure>DPP-4</measure>
    <time_frame>16 weeks</time_frame>
    <description>DPP-4 activity</description>
  </other_outcome>
  <other_outcome>
    <measure>DPP-4</measure>
    <time_frame>8 weeks</time_frame>
    <description>DPP-4 activity</description>
  </other_outcome>
  <other_outcome>
    <measure>ACE</measure>
    <time_frame>16 weeks</time_frame>
    <description>ACE activity</description>
  </other_outcome>
  <other_outcome>
    <measure>ACE</measure>
    <time_frame>8 weeks</time_frame>
    <description>ACE activity</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c (%)</measure>
    <time_frame>16 weeks</time_frame>
    <description>HbA1c (%)</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c (%)</measure>
    <time_frame>8 weeks</time_frame>
    <description>HbA1c (%)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma glucose (mmol/L)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Fasting plasma glucose (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma glucose (mmol/L)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Fasting plasma glucose (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Postprandial plasma glucose (mmol/L)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Postprandial plasma glucose (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Postprandial plasma glucose (mmol/L)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Postprandial plasma glucose (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Free Fatty Acids (FFA) (mmol/L)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Free Fatty Acids (FFA) (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Free Fatty Acids (FFA) (mmol/L)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Free Fatty Acids (FFA) (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin (mg/L)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Insulin (mg/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin (mg/L)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Insulin (mg/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucagon (mg/L)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Glucagon (mg/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucagon (mg/L)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Glucagon (mg/L)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>EMPA/LINA 10/5 mg QD (n=22)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8w EMPA followed by 8w EMPA/LINA 10/5 mg QD (n=22)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LINA/EMPA 5/10 mg QD (N=22)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8w LINA followed by LINA/EMPA 5/10 mg QD (N=22)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gliclazide 30 mg QD/BID (N=22)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8w Gliclazide 30 mg QD, followed by 8w Gliclazide BID (N=22)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EMPA/LINA 10/5 mg QD (n=22)</intervention_name>
    <description>Once daily treatment with oral empagliflozin (Jardiance) 10 mg Once daily treatment with oral linagliptin (Tradjenta) 5 mg</description>
    <arm_group_label>EMPA/LINA 10/5 mg QD (n=22)</arm_group_label>
    <arm_group_label>LINA/EMPA 5/10 mg QD (N=22)</arm_group_label>
    <other_name>Jardiance</other_name>
    <other_name>Tradjenta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LINA/EMPA 5/10 mg QD (N=22)</intervention_name>
    <description>Once daily treatment with oral linagliptin (Tradjenta) 5 mg Once daily treatment with oral empagliflozin (Jardiance) 10 mg</description>
    <arm_group_label>EMPA/LINA 10/5 mg QD (n=22)</arm_group_label>
    <arm_group_label>LINA/EMPA 5/10 mg QD (N=22)</arm_group_label>
    <other_name>Tradjenta</other_name>
    <other_name>Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliclazide 30 mg QD/BID (N=22)</intervention_name>
    <description>Once daily or twice daily treatment with oral glicazide MR 30mg</description>
    <arm_group_label>Gliclazide 30 mg QD/BID (N=22)</arm_group_label>
    <other_name>Gliclazide Sandoz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian*

          -  Both genders (females must be post-menopausal; no menses &gt;1 year; in case of doubt,
             Follicle-Stimulating Hormone (FSH) will be determined with cut-off defined as &gt;31 U/L)

          -  Age: 35 - 75 years

          -  BMI: &gt;25 kg/m2

          -  HbA1c: 7.0 - 9.5% Diabetes Control and Complications Trial (DCCT) or 53 - 80 mmol/mol
             International Federation of Clinical Chemistry (IFCC)

          -  Treatment with a stable dose of oral antihyperglycemic agents for at least 3 months
             prior to inclusion

          -  Metformin monotherapy

          -  Combination of metformin and low-dose SU derivative**

          -  Hypertension should be controlled, i.e. ≤140/90 mmHg, and treated with an ACE-I or ARB
             (unless prevented by adverse effect) for at least 3 months.

          -  Albuminuria should be treated with a RAAS-interfering agent (ACE-I or ARB) for at
             least 3 months.

          -  Written informed consent

               -  In order to increase homogeneity ** In order to accelerate inclusion, patients
                  using combined metformin/SU derivative will be considered. In these patients, a
                  12 week wash-out period of the SU derivative will be observed, only when combined
                  use has led to a HbA1c &lt;8% at screening. Subsequently, patients will be eligible
                  to enter the study, now using metformin monotherapy, provided that HbA1c still
                  meets inclusion criteria.

        Exclusion Criteria:

          -  Estimated GFR &lt;45 mL/min/1.73m2 (determined by the Modification of Diet in Renal
             Disease (MDRD) study equation)

          -  Hemoglobin level &lt; 7.0 mmol/L

          -  Current urinary tract infection and active nephritis

          -  History of unstable or rapidly progressing renal disease

          -  Macroalbuminuria; defined as ACR of &gt;300 mg/g.

          -  Current/chronic use of the following medication: thiazolidinediones, sulfonylurea
             derivatives, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitor, oral
             glucocorticoids, immune suppressants, antimicrobial agents, chemotherapeutics,
             antipsychotics, tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors
             (MOAIs).

          -  Patients on diuretics will only be excluded when these drugs cannot be stopped 3
             months prior randomization and for the duration of the study.

          -  Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) will not be allowed,
             unless used as incidental medication (1-2 tablets) for non-chronic indications (i.e.
             sports injury, head-ache or back ache). However, no such drugs can be taken within a
             time-frame of 2 weeks prior to renal-testing

          -  Pregnancy

          -  History of or actual severe mental disease

          -  History of or actual severe somatic disease (e.g. systemic disease)

          -  History of or actual malignancy (except basal cell carcinoma)

          -  History of or actual pancreatic disease

          -  (Unstable) thyroid disease

          -  Severe hepatic insufficiency and/or significant abnormal liver function defined as
             aspartate aminotransferase (AST) &gt;3x upper limit of normal (ULN)

          -  Recent (&lt;6 months) history of cardiovascular disease, including

               -  Acute coronary syndrome

               -  Stroke or transient ischemic neurologic disorder or chronic heart failure (NYHA
                  grade II-IV)

          -  Complaints compatible with or established neurogenic bladder and/or incomplete bladder
             emptying (as determined by ultrasonic bladder scan)

          -  Substance abuse (alcohol: defined as &gt;3 units alcohol/day)

          -  History of diabetic ketoacidosis (DKA) requiring medical intervention (e.g., emergency
             room visit and/or hospitalization) within 1 month prior to the Screening visit.

          -  Recent blood donation (&lt; 6 months)

          -  Allergy to any of the agents used in the study

          -  Inability to understand the protocol and/or give informed consent

          -  Individuals who are investigator site personnel, directly affiliated with the study,
             or are immediate (spouse, parent, child, or sibling, whether biological or legally
             adopted) family of investigator site personnel directly affiliated with the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark HH Kramer, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michaël JB van Baar, MD</last_name>
    <phone>+31 20 444 4709</phone>
    <email>m.vanbaar@vumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniël H van Raalte, MD PhD</last_name>
    <phone>+31 20 444 0534</phone>
    <email>d.vanraalte@vumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaël JB van Baar, MD</last_name>
      <phone>+31 20 444 4709</phone>
      <email>m.vanbaar@vumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Daniël H van Raalte, MD PhD</last_name>
      <phone>+31 20 444 0534</phone>
      <email>d.vanraalte@vumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Mark HH Kramer, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniël H van Raalte, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>M.H.H. Kramer</investigator_full_name>
    <investigator_title>Head of the Internal Medicine department</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Diabetic kidney disease</keyword>
  <keyword>Diabetic nephropathy</keyword>
  <keyword>Renoprotection</keyword>
  <keyword>SGLT2 inhibitor</keyword>
  <keyword>Empagliflozin</keyword>
  <keyword>DPP-4 inhibitor</keyword>
  <keyword>Linagliptin</keyword>
  <keyword>SU derivative</keyword>
  <keyword>Gliclazide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

